Respiratory & Immunology
In respiratory, AstraZeneca is an established leader, and our respiratory medicines reached more than 53 million patients receiving acute and maintenance therapy in 2019. Building on a 50-year heritage in respiratory care, we aim to transform the treatment of asthma and chronic obstructive pulmonary disease (COPD) by driving earlier, biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death.
But our work is not over. We continue to be carried away by science by developing targeted inhaled and biological therapies, drug combinations and exclusive devices to carry treatments tailored to the needs of patients.
The underlying chronic lung diseases are caused by an altered immune system. AstraZeneca is following the science of common pathways and drivers of underlying diseases from respiratory disease to immunology-driven disease areas.
This is an exciting time to work in the Respiratory and Immunology area at AstraZeneca, as we accelerate our process and reimagine what is possible for people living with these potentially devastating conditions. We have the opportunity to make a huge difference, not only through groundbreaking science, but also by completely transforming the patient experience.
Medical needs not met
Improve patient outcomes with tailored treatments, devices and instruments.
Global burden of respiratory diseases
Raising awareness of the current uncovered medical need in asthma, COPD and idiopathic pulmonary fibrosis (IPF).
Inhaled treatments and novel combinations
Optimizing our portfolio of inhaled medicines products to improve patient choices and outcomes across the spectrum of disease.
Targeted biological treatments
Using new scientific ideas on the biology of respiratory diseases and patient phenotypes to create targeted biological treatments.